keyword
MENU ▼
Read by QxMD icon Read
search

Cardio-oncology

keyword
https://www.readbyqxmd.com/read/29976296/the-cardiologist-and-the-cancer-patient-challenges-to-cardio-oncology-or-onco-cardiology-and-call-to-action
#1
Tochi M Okwuosa, Nicole Prabhu, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Kim A Williams, Agne Paner
No abstract text is available yet for this article.
July 10, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29976295/neoplasia-and-the-heart-pathological-review-of-effects-with-clinical-and-radiological-correlation
#2
REVIEW
Joseph J Maleszewski, Melanie C Bois, John P Bois, Philip M Young, John M Stulak, Kyle W Klarich
The intersection of oncological and cardiovascular diseases is an increasingly recognized phenomenon. This recognition has led to the emergence of cardio-oncology as a true subspecialty. This field is not simply limited to primary cardiac tumors or complications of chemotherapeutic medications. Rather, it also encompasses metastatic cardiovascular complications and secondary cardiovascular effects of the underlying neoplasia. This review will broadly cover primary and metastatic cardiac neoplasms, as well as secondary cardiovascular effects of extracardiac neoplasia (e...
July 10, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29958808/editorial-commentary-update-on-cardio-oncology-novel-cancer-therapeutics-and-associated-cardiotoxicities
#3
EDITORIAL
Juan Lopez-Mattei, Peter Kim, Cezar Iliescu
No abstract text is available yet for this article.
June 19, 2018: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29938321/prevention-of-cardiotoxicities-with-traditional-and-novel-chemotherapeutic-agents
#4
REVIEW
Zarina Sharalaya, Patrick Collier
PURPOSE OF REVIEW: This review will discuss strategies to prevent cardiotoxicity associated with chemotherapeutics. Forty years ago, investigators identified dose-dependent cardiotoxicity related to anthracycline-based regimens. Over recent decades, the development of more selective, mechanism-based chemotherapeutics has been associated with both on-target and off-target adverse cardiovascular sequelae. RECENT FINDINGS: Strategies to prevent or attenuate cardiotoxicities include limitation of anthracycline dose, appropriate patient selection, referral/access to cardio-oncology programs, early recognition of cardiac side effects, active cardio-surveillance, cardio-protective medical therapy, treatment-specific concerns, and follow-up...
June 25, 2018: Current Heart Failure Reports
https://www.readbyqxmd.com/read/29931556/acute-coronary-syndrome-in-cancer-patients
#5
REVIEW
Begum Yetis Sayin, Mehmet Ali Oto
Cardiologists are seeing an increasing number of oncology patients every day, and acute coronary syndrome (ACS) is one of the problems patients encounter during follow-up. Cardio-oncology is the care of patients with cancer and cardiovascular disease, whether overt or occult, already established or acquired during treatment. Cardiovascular complications can occur acutely during or shortly after treatment and persist as long-term effects for months to years after treatment. As a delayed effect of cancer treatment, cardiovascular damage can occur months to years after the initial treatment...
June 22, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29929621/cardio-oncology-for-gennext-a-missing-piece-of-the-training-puzzle
#6
EDITORIAL
Sarju Ganatra, Salim S Hayek
No abstract text is available yet for this article.
June 26, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29910109/update-on-cardio-oncology-novel-cancer-therapeutics-and-associated-cardiotoxicities
#7
REVIEW
Avirup Guha, Merna Armanious, Michael G Fradley
There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies...
June 8, 2018: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29909111/optimal-treatment-of-stage-b-heart-failure-in-cardio-oncology-the-promise-of-strain
#8
EDITORIAL
Ana Barac
No abstract text is available yet for this article.
June 8, 2018: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29868614/interventional-cardio-oncology-adding-a-new-dimension-to-the-cardio-oncology-field
#9
Victor Y Liu, Ali M Agha, Juan Lopez-Mattei, Nicolas Palaskas, Peter Kim, Kara Thompson, Elie Mouhayar, Konstantinos Marmagkiolis, Saamir A Hassan, Kaveh Karimzad, Cezar A Iliescu
The management of cardiovascular disease in patients with active cancer presents a unique challenge in interventional cardiology. Cancer patients often suffer from significant comorbidities such as thrombocytopenia and coagulopathic and/or hypercoagulable states, which complicates invasive evaluation and can specifically be associated with an increased risk for vascular access complications. Furthermore, anticancer therapies cause injury to the vascular endothelium as well as the myocardium. Meanwhile, improvements in diagnosis and treatment of various cancers have contributed to an increase in overall survival rates in cancer patients...
2018: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29806680/-cardiotoxicity-of-anticancer-therapies-towards-the-implementation-of-cardio-oncology-units
#10
René Hameau, Luigi Gabrielli, Marcelo Garrido, Ana María Guzmán, Ignacio Retamal, María José Vacarezza, Douglas Greig, Mauricio Ocqueteau, César Sánchez, Marcela Pizarro, Alejandro Corvalán, Sergio Lavandero, Pablo F Castro, Gonzalo Martínez
Recently, we have witnessed major improvements in cancer treatment. Early diagnosis and development of new therapies have reduced cancer-related mortality. However, these new therapies, along with greater patient survival, are associated with an increase in untoward effects, particularly in the cardiovascular system. Although cardiotoxicity induced by oncologic treatments affects predominantly the myocardium, it can also involve other structures of the cardiovascular system, becoming one of the main causes of morbidity and mortality in those who survive cancer...
January 2018: Revista Médica de Chile
https://www.readbyqxmd.com/read/29802472/biomarker-discovery-in-cardio-oncology
#11
REVIEW
Anita Vohra, Aarti Asnani
PURPOSE OF REVIEW: In this article, we review current and emerging approaches to biomarker discovery to facilitate early diagnosis of cancer therapy-associated cardiovascular toxicity. RECENT FINDINGS: Although small studies have demonstrated an association between established biomarkers of cardiac injury (troponins and brain natriuretic peptide) and acute or subacute cardiotoxicity, there is insufficient evidence to support their use in routine clinical care. Preclinical studies to define the molecular mechanisms of cardiotoxicity, as well as the use of unbiased "omics" techniques in small patient cohorts, have yielded promising candidate biomarkers that have the potential to enrich current risk stratification algorithms...
May 25, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29783917/capecitabine-induced-myopericarditis-a-case-report-and-review-of-literature
#12
Sydney Saunders, Maria Anwar
Objective To describe a possible case of capecitabine-induced myopericarditis in a patient at the Cardio-Oncology Clinic in Calgary, AB. Design A literature search and adverse drug reaction assessment with the Naranjo tool was conducted. Results A 39-year-old male with recurrent locally advanced rectal adenocarcinoma presented two days after adjuvant treatment with capecitabine and oxaliplatin complaining of intermittent, severe interscapular pain. Based on symptoms, laboratory investigations, and imaging, the patient was diagnosed with acute myopericarditis...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29752960/assessment-of-herb-drug-synergy-to-combat-doxorubicin-induced-cardiotoxicity
#13
Aditi Jain, Vibha Rani
Aim Doxorubicin (Dox) is one of the most cardiotoxic anti-cancerous drug that is widely used for broad-range of cancers. There is an urgent need for developing cardio-oncological therapeutic interventions. Natural products having both anti-cancerous potential as well as cardioprotective effects may hold a great potential in this regard. Curcuma longa (an Indian herb) polyphenols including curcumin, and well known for its anti-oxidative and anti-cancerous potential was used in the present study for its synergistic effect on cancer cells and cardiomyocytes...
July 15, 2018: Life Sciences
https://www.readbyqxmd.com/read/29720563/pharmacology-of-cardio-oncology-chronotropic-and-lusitropic-effects-of-b-type-natriuretic-peptide-in-cancer-patients-with-early-diastolic-dysfunction-induced-by-anthracycline-or-nonanthracycline-chemotherapy
#14
Pierantonio Menna, Vito Calabrese, Grazia Armento, Ombretta Annibali, Carlo Greco, Emanuela Salvatorelli, Francesco Marchesi, Giorgio Reggiardo, Giorgio Minotti
B-type natriuretic peptide (BNP) is widely used as a diagnostic marker of systolic dysfunction. We previously conducted a clinical study in which anthracycline or nonanthracycline chemotherapy did not cause systolic dysfunction in cancer patients; however, some patients showed asymptomatic alterations in diastolic relaxation, whereas others showed persistent elevations of BNP, measured as prohormone BNP amino-terminal fragment. Here we describe post hoc pharmacologic analyses showing that: 1) impaired relaxation and persistent elevations of BNP were mutually exclusive manifestations of diastolic dysfunction; 2) in some patients, BNP elevations were induced by an early compromise of myocardial relaxation; 3) BNP elevations then halted further deterioration of relaxation in a concentration-dependent manner; and 4) high BNP increased heart rate (HR)...
July 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29708912/chemotherapy-induced-cardiotoxicity-new-insights-into-mechanisms-monitoring-and-prevention
#15
Christian Cadeddu Dessalvi, Martino Deidda, Donato Mele, Pier P Bassareo, Roberta Esposito, Ciro Santoro, Maria Lembo, Maurizio Galderisi, Giuseppe Mercuro
: Chemotherapy-induced cardiotoxicity (CTX) remains a determining factor for the quality of life and mortality of patients treated with potentially cardiotoxic drugs. Considerable advances have been made in this field with increase in awareness regarding chemotherapy-induced CTX, which has changed the treatment approach to include cardiovascular risk among the first factors to be evaluated before therapy. Moreover, a better understanding of the pathophysiology of chemotherapy-induced CTX has also facilitated early identification of patients at risk with the help of new imaging technologies...
July 2018: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/29644475/electrophysiologic-toxicity-of-chemoradiation
#16
REVIEW
Merna A Armanious, Shreya Mishra, Michael G Fradley
PURPOSE OF REVIEW: There is growing awareness of the link between oncology treatments and cardiovascular (CV) complications. This has led to the development of cardio-oncology, a specialty aimed at managing CV risk and disease in cancer patients and survivors. Cardiac arrhythmias are potential adverse CV complications of cancer treatments; however, these cardiotoxicities are often underappreciated due to the uncertain arrhythmogenic mechanisms of various chemotherapeutic agents. RECENT FINDINGS: Chemotherapeutic agents can induce arrhythmias via direct electrophysiological effects on ion channels or intracellular signaling pathways, or indirectly from cardiac tissue damage...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29629020/diagnosis-treatment-and-prevention-of-cardiovascular-toxicity-related-to-anti-cancer-treatment-in-clinical-practice-an-opinion-paper-from-the-working-group-on-cardio-oncology-of-the-korean-society-of-echocardiography
#17
REVIEW
Hyungseop Kim, Woo-Baek Chung, Kyoung Im Cho, Bong-Joon Kim, Jeong-Sook Seo, Seong-Mi Park, Hak Jin Kim, Ju-Hee Lee, Eun Kyoung Kim, Ho-Joong Youn
Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity...
March 2018: Journal of Cardiovascular Ultrasound
https://www.readbyqxmd.com/read/29550304/is-there-added-value-of-the-third-imaging-dimension-in-cardio-oncology
#18
EDITORIAL
Paaladinesh Thavendiranathan
No abstract text is available yet for this article.
March 9, 2018: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29530893/exercise-therapy-and-cardiovascular-toxicity-in-cancer
#19
REVIEW
Jessica M Scott, Tormod S Nilsen, Dipti Gupta, Lee W Jones
Cardio-oncology is an emerging discipline focused predominantly on the detection and management of cancer treatment-induced cardiac dysfunction (cardiotoxicity), which predisposes to development of overt heart failure or coronary artery disease. The direct adverse consequences, as well as those secondary to anticancer therapeutics, extend beyond the heart, however, to affect the entire cardiovascular-skeletal muscle axis (ie, whole-organism cardiovascular toxicity). The global nature of impairment creates a strong rationale for treatment strategies that augment or preserve global cardiovascular reserve capacity...
March 13, 2018: Circulation
https://www.readbyqxmd.com/read/29528869/cardio-oncology-organization-patterns-in-italy-one-size-does-not-fit-all
#20
Maria Laura Canale, Chiara Lestuzzi, Irma Bisceglia, Paola Vallerio, Iris Parrini
AIMS: Cardio-oncology is imposing as the specialty deputed to the management of a large and rapidly increasing population of cancer patients receiving anticancer treatments with cardiovascular side effects or presenting with cardiac and oncological comorbidities. Organization patterns dramatically vary across Italy. METHODS: On the behalf of ANMCO, we have analyzed the characteristics of cardio-oncology services across different hospital types in Italy. A questionnaire was sent out to all ANMCO divisions inquiring about inner organization, workload, multidisciplinary team and inter-hospital connections...
May 2018: Journal of Cardiovascular Medicine
keyword
keyword
50
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"